Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Emmanuelle Waubant, MD PhD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05122559CT.gov Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis | — | Active Not Recruiting | — | — | — |
NCT03109288CT.gov Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Acetylcysteine (this asset) | Emmanuelle Waubant, MD PhD | P2 | CCC · 52 |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Fingolimod | Biogen | P4 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Acetylcysteine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | — | P4 | BBB · 74 |
| Schizophreniform Disorder | — | P4 | BBB · 74 |
| Pulmonary Fibrosis | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Acetylcysteine in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/acetylcysteine-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →